17-Acetoxyjolkinolide B irreversibly inhibits IkappaB kinase and induces apoptosis of tumor cells

Mol Cancer Ther. 2008 Jun;7(6):1523-32. doi: 10.1158/1535-7163.MCT-08-0263.

Abstract

Nuclear factor-kappaB (NF-kappaB) is critically important for tumor cell survival, growth, angiogenesis, and metastasis. One of the key events in the NF-kappaB signaling is the activation of inhibitor of NF-kappaB kinase (IKK) in response to stimuli of various cytokines. We have identified 17-acetoxyjolkinolide B (17-AJB) from a traditional Chinese medicinal herb Euphorbia fischeriana Steud as a novel small-molecule inhibitor of IKK. 17-AJB effectively inhibited tumor necrosis factor-alpha-induced NF-kappaB activation and induced apoptosis of tumor cells. 17-AJB had no effect on binding of tumor necrosis factor-alpha to its receptor or on binding of NF-kappaB to DNA. It inhibited NF-kappaB nuclear translocation. Detailed analysis revealed that the direct target of 17-AJB was IKK. 17-AJB kept IKK in its phosphorylated form irreversibly. This irreversible modification of IKK inactivated its kinase activity, leading to its failure to activate NF-kappaB. The effect of 17-AJB on IKK was specific. It had no effect on other kinases such as p38, p44/42, and JNK. In addition, 17-AJB induced apoptosis in tumor cells. The effects of 17-AJB on apoptosis correlated with inhibition of expression of the NF-kappaB-regulated genes. Taken together, our data suggest that 17-AJB is a novel type NF-kappaB pathway inhibitor. Its unique interaction mechanism with IKK may render it a strong apoptosis inducer of tumor cells and a novel type anticancer drug candidate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects*
  • Cell Line, Tumor
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Cytokines / pharmacology
  • DNA, Neoplasm / metabolism
  • Diterpenes / chemistry
  • Diterpenes / pharmacology*
  • Diterpenes / therapeutic use
  • Doxorubicin / pharmacology
  • Drug Synergism
  • Gene Expression Regulation, Neoplastic
  • Humans
  • I-kappa B Kinase / antagonists & inhibitors*
  • I-kappa B Proteins / metabolism
  • NF-kappa B / metabolism
  • Neoplasms / drug therapy
  • Neoplasms / enzymology*
  • Neoplasms / pathology*
  • Phosphorylation / drug effects
  • Phytotherapy
  • Protein Binding / drug effects
  • Protein Processing, Post-Translational / drug effects
  • Protein Transport / drug effects
  • Receptors, Tumor Necrosis Factor / metabolism
  • Signal Transduction / drug effects
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • 17-acetoxyjolkinolide B
  • Antineoplastic Agents
  • Cytokines
  • DNA, Neoplasm
  • Diterpenes
  • I-kappa B Proteins
  • NF-kappa B
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • jolkinolide B
  • Doxorubicin
  • I-kappa B Kinase